1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy

Information

  • Patent Application
  • 20080167313
  • Publication Number
    20080167313
  • Date Filed
    March 02, 2006
    18 years ago
  • Date Published
    July 10, 2008
    16 years ago
Abstract
The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by groups such as trifluoromethyl, C5-C6 cycloalkyl, nitrile, C1-C4 alkoxycarbonylvinyl, hydroxycarbonylvinyl, C1-C4 alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C1-C4 alkoyl, C1-C4 alkoxy, nitro, halogen, trifluoromethyl); YR3 represents oxygen or NR3 for which R3 represents hydrogen, a linear or branched C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by groups such as trifluoromethyl or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C1-C4 alkoyl, C1-C4 alkoxy, nitro, halogen, trifluoromethyl); Z represents an oxygen atom or a carbon atom capable of being bound to the ortho, meta or para positions of the phenyl group of formula I; n can be 0 to 5 when Z=C or 2 to 4 when Z=O; X represents oxygen or sulphur; R4, R5, R6, R7 and R8 represent hydrogen or fluorine; R9, R10 and R11 represent hydrogen or a linear or branched C1-C5 alkyl group as well as the pharmaceutically acceptable base addition salts, and the various enantiomers of compounds having asymmetric carbons, and their mixtures in all proportions including in particular the racemic mixtures.
Description

The present invention has as an aim new derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine functionalized at 2, 4 and 6 which activate PPAR alpha and/or gamma receptors, their preparation and their application in human therapeutics.


Metabolic syndrome is the result of a peripheral resistance to increased insulin and is characterized by hyperinsulinemia, intolerance to glucose, change in lipid metabolism and arterial hypertension (Grundy, S. M.: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 1999, 83, 25F-29F). Obesity is often associated with these metabolic disorders, and the conjunction of these multiple risk factors favors the development of the atheromatosis at the origin of arterial thrombosis, today the number one cause of mortality in industrialized areas. Peroxisome proliferator-activated receptors (PPAR) belong to the superfamily of transcription factor nuclear receptors. After activation, they form heterodimers with 9-cis retinoic acid receptor (RXR); this complex (PPAR-RXR) is linked specifically with DNA sequences located in the regulatory regions of genes implicated in the metabolism of lipids and carbohydrates (Pineda Torra, I., Gervois, P. and Staels, B.: Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 1999, 10, 151-159. Vamecq, J. and Latruffe, N.: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999, 354, 141-148.). PPAR activation, on the one hand, restores certain altered metabolic pathways that predispose to atherosclerosis, and on the other reduces the inflammatory events which favor atheroma plaque development and rupture.


The compounds of the present invention are characterized by their original structure, their affinity with respect to alpha and/or gamma PPAR receptors and their pharmacological profile.


The compounds of the invention correspond to the general formula I.







in which

    • R1 and R2 can be identical or different and represent an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl, cycloalkyl at C5-C6, nitrile, alkoxycarbonylvinyl at C1-C4, hydroxycarbonylvinyl, alkoxycarbonyl at C1-C4, carboxylate, benzyloxy or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C1-C4, alkoxy at C1-C4, nitro, halogen or trifluoromethyl),
    • YR3 represents oxygen or NR3 in which R3 represents hydrogen, an alkyl or alkenyl radical, linear or branched at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C1-C4, alkoxy at C1-C4, nitro, halogen or trifluoromethyl),
    • Z represents an oxygen atom or a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I,
    • n can range from 0 to 5 when Z=C or from 2 to 4 when Z=O,
    • X represents oxygen or sulfur,
    • R4, R5, R6, R7 and R8 represent hydrogen or fluorine,
    • R9, R10 and R11 represent hydrogen or an alkyl group, linear or branched, at C1-C5,


      as well as additive salts with pharmaceutically acceptable bases and the various enantiomers of compounds having asymmetrical carbons, as well as their mixtures in all proportions, including racemic mixtures in particular.


The invention relates, in particular, to the compounds of formula I in which:

    • R1 and R2 represent, independently one from the other, an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl, cycloalkyl at C6, nitrile, or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C1-C4, alkoxy at C1-C4, nitro, halogen or trifluoromethyl),
    • YR3 represents oxygen or NR3 in which R3 represents hydrogen, an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl or phenyl,
    • Z represents an oxygen atom or a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I
    • n can range from 0 to 5 when Z=C or from 2 to 4 when Z=O,
    • X represents oxygen or sulfur,
    • R4, R5, R6, R7 and R8 represent hydrogen or fluorine,
    • R9, R10 and R11 represent hydrogen or an alkyl group, linear or branched, at C1-C5.


The invention relates, more particularly, to the compounds of formula I in which:

    • R1 and R2 represent independently one from the other, an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl or nitrile,
    • YR3 represents oxygen or NR3 in which R3 represents hydrogen or a linear or branched alkyl radical at C1-C7,
    • Z represents a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I,
    • n can range from 0 to 5,
    • X represents oxygen or sulfur,
    • R4, R5, R6, R7 and R8 represent hydrogen or fluorine,
    • R9, R10 and R11 represents hydrogen or a linear or branched alkyl group at C1-C5, in particular R9 and R10 represent a methyl group and R11 hydrogen or an ethyl group.


The invention relates still more particularly to the derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine of formula I in which:

    • R1 and R2 represent independently one from the other, an alkyl or alkenyl radical, linear or branched, at C1-C7, possibly substituted at the end of the chain by a trifluoromethyl group,
    • YR3 represents oxygen or NR3 in which R3 represents hydrogen or a linear or branched alkyl radical at C1-C7,
    • Z represents a carbon atom which can be bound in meta or para position on the phenyl group of formula I,
    • n can range from 1 to 5,
    • X represents oxygen or sulfur,
    • R4 to R8 represent hydrogen,
    • R9 and R10 represent a methyl radical
    • R11 represents hydrogen or an ethyl radical.


The invention encompasses salts of the compounds of general formula I with pharmaceutically acceptable bases, as well as the various enantiomers of compounds possessing asymmetrical carbons, as well as their mixtures in all proportions including racemic mixtures in particular.


Synthesis

The compounds of the present invention can be synthesized by using the synthetic pathways described below or by using synthesis methods known to those skilled in the art.


Method 1

The synthesis of compounds of general formula I is characterized (diagram 1) wherein a derivative of general formula II is condensed







in which R1 and R2 represent the groups as previously described in formula I with a derivative of general formula III







where YR3, n, Z, X, R4, R5, R6, R7, R8, R9, R10 and R11 are such as described previously in formula I. This reaction can be carried out in the presence of a base such as triethylamine in n-butanol (when Y═N) or potassium carbonate in dimethylformamide (when YR3═O);







Method 2

This synthesis method for compounds of general formula I for which Z=O (diagram 2) is characterized wherein:


1) a derivative of general formula II is condensed







in which R1 and R2 represent the groups as previously described in formula I with a derivative of general formula IV







in which R3Y can be equal to NH or O and n is such as described previously in formula I. This reaction can be carried out in the absence of solvent without adding base (in the case where R3Y═NH) or in the presence of a base such as K2CO3 (in the case where R3Y═O).


2) the derivative obtained V is condensed







with a compound of general formula VI







where X, R4, R5, R6, R7, R8, R9, R10 and R11 are as described previously in formula I. This reaction can be carried out under conditions such as those of the Mitsunobu reaction in the presence of triphenylphosphine and diethylazodicarboxylate in THF.







Method 3

This synthesis method for compounds of general formula I for which Z=O (diagram 3) is characterized wherein:


1) the alcohol function of a derivative of general formula VII is protected







in which R1, R2 and n are as described previously in formula I by a protection group such as tert-butyldimethylsilane. This reaction can be carried out under conditions such as THF by using chlorotertbutyldimethylsilane and imidazole.







2) the nitrogen of compound VIII previously obtained is alkylated by a halogenated derivative R3Hal in which the Hal group represents a halogen such as Cl, Br or I and R3 is as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.







3) the compound IX thus obtained is deprotected under operating conditions such as tetrabutylammonium fluoride in THF.


4) the derivative obtained X is condensed







with a compound of general formula VI







where X, R4, R5, R6, R7, R8, R9, R10 and R11 are as described previously in formula I. This reaction can be carried out under conditions such as those of the is Mitsunobu reaction in the presence of triphenylphosphine and diethylazodicarboxylate in THF.







Method 4

This method is implemented when Y═N and Z=C and it is characterized (diagram 4) wherein:


1) a derivative of general formula II is condensed







in which R1 and R2 represent the groups as previously described in formula I with a derivative of general formula XI







in which n, R3 R4, R5, R6, R7 and R8 are as described previously in formula I and A can be hydrogen or a methyl group. This reaction can be carried out in the presence of a base such as triethylamine in n-butanol.


2) after demethylation (if A=Me, under conditions such as BBr3 in dichloromethane), the phenol function of derivative XII is alkylated







by a halogenated derivative of general formula XIII (used as a solvent in the presence of a base such as potassium carbonate)







in which the Hal group represents a halogen such as Cl, Br or I, and R9, R10 and R11 are as previously described in general formula I.







Method 5

This method is implemented when Y═N and Z=C and it is characterized (diagram 5) wherein:


1) a derivative of general formula XIV is alkylated







in which R1, R2, R4, R5, R6, R7, R8 et n are as described previously in formula I with a derivative of formula R3Hal in which the Hal group represents a halogen such as Cl, Br or I and R3 is as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.


2) after demethylation under conditions such as BBr3 in dichloromethane, the phenol function of the derivative XII thus obtained is alkylated







by a halogenated derivative of general formula XIII (used as a solvent in the presence of a base such as potassium carbonate)







in which the Hal group represents a halogen such as Cl, Br or I, and R9, R10 and R11 are as previously described in general formula I.







Method 6

This method is characterized (diagram 6) wherein:


1) a derivative of general formula XIV is placed







in which R1═(CH2)2CN and R2, R3, n, Z, X, R4, R5, R6, R7, R8, R9, R10 and R11 are as described previously in formula I or R2═(CH2)2CN and R1, R3, n, Z, X, R4, R5, R6, R7, R8, R9, R10 and R11 are as described previously in formula I under operating conditions such as in the presence of a base NaH in DMF.


2) the nitrogen of the triazine of derivative XIVa or XIVb thus obtained is then alkylated







by a halogenated derivative of general formula R1Hal in the case of the intermediate XIVa and of general formula R2Hal in the case of the intermediate XIVb in which the Hal group represents a halogen such as Cl, Br or I and R1 and R2 are as described previously in formula I, under operating conditions such as NaH or tBuOK in DMF.







If desired, the intermediate and final compounds can be purified according to one or more purification methods chosen among extraction, filtration, silica gel chromatography, normal or reverse phase preparative HPLC and crystallization.


The raw materials used in the methods described previously are commercially available or easily accessible to those skilled in the art according to methods described in the literature.


The following examples illustrate the invention without limiting its scope.


Elementary analyses and IR and NMR spectra confirm the compounds' structures.


Intermediates
Intermediate 1:
a) 6-Bromo-2H-[1,2,4]triazine-3,5-dione (1a)






2H-[1,2,4]triazin-3,5-dione (50 g, 442 mmol) is placed in the presence of 60 ml of bromine in 800 ml of water at 60° C. for 10 h. The reaction medium is then slowly added to an ammonia solution until pH=5. It is then extracted in ethyl acetate and the organic phases are dried on MgSO4. After filtration and dry concentration, 1a is isolated in the form of a white solid (79.2 g, yield=93%). TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 90:10, Rf=0.32.


b) 6-Bromo-2,4-dimethyl-2H-[1,2,4]triazine-3,5-dione (1b)






11.8 g (295 mmol) of NaH (60% in paraffin) is placed in suspension at 0° C. in 250 ml of DMF under nitrogen. 25.80 g (135 mmol) of intermediate 1a diluted in 150 ml of DMF is added drop by drop. This solution is then placed at ambient temperature and 18.4 ml (296 mmol) of methyl iodide is added dropwise. After a night of stirring and after dry concentration of the reaction medium, the residue obtained is taken up in water and extracted with ethyl acetate. The organic phases are washed with brine, dried on magnesium sulfate then dry concentrated. The residue obtained, taken up in ether, crystallizes and a first crystal fraction is isolated. The filtrate is dry concentrated the purified by plash chromatograph on silica (heptane:AcOEt 50:50). 24 g of intermediate 1b are thus isolated (81% yield) TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 80:20, Rf=0.59.


c) Intermediates (1c)-(1g)






The synthesis of intermediates 1c-1g is carried out starting from 1a according to the procedure described for the synthesis of 1b by using various alkylation agents RX.









TABLE 1







intermediates 1c-1g















Intermediates


RX
Yield
TLC
State
1c-1g










80%
PE:AcOEt 80:20Rf = 0.42
oil
1c: 6-Bromo-2,4-dibutyl-2H-[1,2,4]triazine-3,5-dione










95%
PE:AcOEt 80:20Rf = 0.75
solid
1d: 6-Bromo-2,4-bis-(4,4,4-trifluoro-butyl)-2H-[1,2,4]-triazine-3,5-dione










95%
PE:AcOEt 90:10Rf = 0.81
oil
1e: 6-Bromo-2,4-diheptyl-2H-[1,2,4]triazine-3,5-dione










92%
PE:AcOEt 90:10Rf = 0.82
oil
1f: 6-Bromo-2,4-bis-(3-cyclohexyl-propyl)-2H-[1,2,4]triazine-3,5-dione










98%
PE:AcOEt 70:30Rf = 0.62
oil
1g: 2,4-Bis-benzyloxymethyl-6-bromo-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 2:
a) 6-Bromo-4-methyl-2H-[1,2,4]triazine-3,5-dione (2a)






20.3 g (105.7 mmol) of triazine 1a are placed in 150 ml of acetic anhydride at reflux for 4.5 h. After dry concentration of the reaction medium, a precipitate is isolated then recrystallized in ether: 24.3 g of crystals are isolated (yield=98%). 4.5 g (114.2 mmol) of NaH (60% in paraffin) are placed in 50 ml of DMF under nitrogen. A solution of 24.3 g (103.8 mmol) of crystals isolated previously in 150 ml of DMF is added dropwise. The reaction medium is stirred for 45 nm at ambient temperature and then 7 ml (114.2 mmol) of methyl iodide are added; stirring is then continued for 21 h at ambient temperature. After dry concentration, the residue obtained is taken up in H2O and extracted with ethyl acetate. After drying on MgSO4, the organic phases are evaporated and the clear oil obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 90:10). 22.9 g of crystals (yield=89%) are isolated and are placed in 300 ml of ethanol in the presence of 0.6 g of p-toluene sulfonic acid. This mixture is heated at reflux for 4.5 h and then dry concentrated. The residue is taken up in H2O and extracted with ethyl acetate. After drying and evaporation of the organic phases, 17 g of intermediate 2a is isolated in the form of a solid (yield=89%). TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.29.


b) Intermediates (2b)-(2f)






The synthesis of intermediates 2b-2f is carried out starting from 1a according to the procedure described for the synthesis of 2a by using various alkylation agents RX.









TABLE 2







intermediates 2b-2f












Total


Intermediates


RX
yield
TLC
State
2b-2f










73%
PE:AcOEt 80:20Rf = 0.28
solid
2b: 6-Bromo-4-butyl-2H-[1,2,4]triazine-3,5-dione










60%
PE:AcOEt 80:20Rf = 0.26
solid
2c: 6-Bromo-4-(3-methyl-but-2-enyl)-2H-[1,2,4]triazine-3,5-dione










76%
CH2Cl2:AcOEt90:10Rf = 0.45
solid
2d: 6-Bromo-4-(4,4,4′-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione










84%
PE:AcOEt 70:30Rf = 0.73
solid
2e: 6-Bromo-4-heptyl-2H-[1,2,4]triazine-3,5-dione










82%
PE:AcOEt 70:30Rf = 0.25
solid
2f: 4-Benzyl-6-bromo-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 3:
a) 3-(6-Bromo-4-methyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-propionitrile (3a)






2.4 g (11.6 mmol) of triazine 2a and 7 ml (106 mmol) of acrylonitrile are placed in 24 ml of a solution of pyridine and water (1:1) at reflux for 3 h. After concentration the reaction medium is extracted by AcOEt, and after drying on MgSO4 the organic phases are dry concentrated. 2.8 g of solid 3a are isolated and then washed with ether (yield=93%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.18.


b) Intermediates 3b and 3c






The synthesis of intermediates 3b and 3c is carried out starting from intermediates 2d and 2e, respectively, following the procedure described for the synthesis of 3a.









TABLE 3







intermediates 3b and 3c











Starting






molecule
Yield
TLC
State
Intermediates 3b-3c





2d
91%
PE:AcOEt 70:30
solid
3b: 3-[6-Bromo-3,5-dioxo-




Rf = 0.34

4-(4,4,4-trifluoro-butyl)-






4,5-dihydro-3H-






[1,2,4]triazin-2-yl]-






propionitrile


2e
95%
CH2Cl2:AcOEt
solid
3c: 3-(6-Bromo-4-heptyl-




70:30

3,5-dioxo-4,5-dihydro-3H-




Rf = 0.51

[1,2,4]triazin-2-yl)-






propionitrile





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 4:
d) 6-Bromo-4-methyl-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione (4a)






0.85 g (21.3 mmol) of NaH (60% in paraffin) is placed in 10 ml of DMF under nitrogen. A solution of 4 g (19.4 mmol) of intermediate 2a in 40 ml of DMF is added dropwise. The reaction medium is stirred for 1 h at ambient temperature and then 5 g (21.3 mmol) of 1,1,1-trifluoro-4-iodo-butane are added; stirring is then continued for 3 h at ambient temperature. After dry concentration, the residue obtained is taken up in H2O and extracted with ethyl acetate. After drying on MgSO4, the organic phases are evaporated and the oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 5.3 g of crystals corresponding to compound 4a are isolated (yield=87%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.58.


d) 6-Bromo-2-heptyl-4-methyl-2H-[1,2,4]triazine-3,5-dione (4b)






The synthesis of intermediate 4b is carried out starting from 2a according to the procedure described for the synthesis of 4a by using 1-bromoheptane for the alkylation step (yield=91%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.76.


Intermediate 5:






The synthesis of intermediates 5a-5d is carried out starting from intermediates 2b and 2c according to the procedure described for the synthesis of 4a by using various halogenated derivatives R1X.









TABLE 4







intermediates 5a-5d















Intermediates


R1X
Yield
TLC
State
5a-5c





—I
64%
CH2Cl2:AcOEt
solid
5a: 6-Bromo-4-butyl-2-




95:5

methyl-2H-




Rf = 0.75

[1,2,4]triazine-3,5-dione










95%
PE:AcOEt80:20Rf = 0.61
oil
5b: 6-Bromo-4-butyl-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione










72%
PE:AcOEt 80:20Rf = 0.75
oil
5c: 6-Bromo-4-butyl-2-heptyl-2H-[1,2,4]triazine-3,5-dione










90%
PE:AcOEt 80:20Rf = 0.58
oil
5d: 6-Bromo-4-(3-methyl-but-2-enyl)-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 6:






The synthesis of intermediates 6a-6c is carried out starting from intermediate 2d according to the procedure described for the synthesis of 4a by using various halogenated derivatives RX.









TABLE 5







intermediates 6a-6c















Intermediates


RX
Yield
TLC
State
6a-6b





—I
91%
PE:AcOEt 70:30
solid
6a: 6-Bromo-2-methyl-4-




Rf = 0.61

(4,4,4-trifluoro-






butyl)-2H-






[1,2,4]triazine-3,5-






dione










88%
PE:AcOEt 60:40Rf = 0.53
oil
6b: 6-Bromo-2-heptyl-4-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione










80%
PE:AcOEt 60:40Rf = 0.43
oil
6c: 6-Bromo-2-(3-cyclohexyl-propyl)-4-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 7:






The synthesis of intermediates 7a-7d is carried out starting from intermediate 2e according to the procedure described for the synthesis of 4a by using various halogenated derivatives RX.









TABLE 6







intermediates 7a-7d















Intermediates


RX
Yield
TLC
State
7a-7d





—I
92%
CH2Cl2:MeOH
oil
7a: 6-Bromo-4-heptyl-2-




95-5

methyl-2H-




Rf = 0.65

[1,2,4]triazine-3,5-






dione










98%
PE:AcOEt 70:30Rf = 0.81
oil
7b: 6-Bromo-4-heptyl-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione










80%
PE:AcOEt 80:20Rf = 0.60
oil
7c: 2-Benzyl-6-bromo-4-heptyl-2H-[1,2,4]triazine-3,5-dione










78%
PE:AcOEt 80:20Rf = 0.59
oil
7d: 6-Bromo-2-cyclohexylmethyl-4-heptyl-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 8:






The synthesis of intermediates 8a-8b is carried out starting from intermediate 2f according to the procedure described for the synthesis of 4a by using various halogenated derivatives RX.









TABLE 7







intermediates 8a-8b















Intermediates


RX
Yield
TLC
State
8a-8b










93%
PE:AcOEt 80:20Rf = 0.46
oil
8a: 4-Benzyl-6-bromo-2-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione










98%
PE:AcOEt 80:20Rf = 0.66
oil
8b: 4-Benzyl-6-bromo-2-heptyl-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 9:
a) 6-(2-Hydroxy-ethylamino)-2,4-bis-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione (9a)






3 g (7.3 mmol) of triazine 1d are placed in 1.3 ml of ethanolamine at 130° C. for 5 h. After cooling, 50 ml of water are added to the reaction medium which is then extracted with AcOEt. After drying on MgSO4, the organic phases are dry concentrated and the residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 70:30). 1.9 g of oil corresponding to intermediate 9a is thus isolated (66% yield). TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 70:30, Rf=0.28.


b) Intermediates 9b-9l






The synthesis of intermediates 9b-9l is carried out from the starting compounds listed in table 8 following the procedure described for the synthesis of 9a.









TABLE 8







intermediates 9b-9l












Starting
Amino






molecule
alcohol
Yield
TLC
State
Intermediates 9b-9k





4b
Ethanol-
77%
CH2Cl2:AcOEt
solid
9b: 2-Heptyl-6-(2-



amine

60:40

hydroxy-ethylamino)-





Rf = 0.28

4-methyl-2H-







[1,2,4]triazine-3,5-dione


1e
Ethanol-
67%
PE:AcOEt 70:30
oil
9c: 2,4-Diheptyl-6-



amine

Rf = 0.56

(2-hydroxy







ethylamino)-2H-







[1,2,4]triazine-3,5-dione


1f
Ethanol-
56%
PE:AcOEt 80:20
oil
9d: 2,4-Bis-(3-



amine

Rf = 0.18

cyclohexyl-propyl)-6-







(2-hydroxy-ethyl-amino)-2H-







[1,2,4]triazine-3,5-dione


1b
Amino-
18%
AcOEt
oil
9e: 6-(3-Hydroxy-



propanol

Rf = 0.42

propyl-amino)-2,4-







dimethyl-2H-







[1,2,4]triazine-3,5-dione


4a
Amino-
44%
PE:AcOEt 70:30
solid
9f: 6-(3-Hydroxy-



propanol

Rf = 0.13

propylamino)-4-







methyl-2-(4,4,4-







trifluoro-butyl)-2H-







[1,2,4]triazine-3,5-dione


4b
Amino-
67%
CH2Cl2:AcOEt
solid
9g: 2-Heptyl-6-(3-



propanol

60:40

hydroxy-propylamino)-





Rf = 0.32

4-methyl-2H-







[1,2,4]triazine-3,5-dione


6a
Amino-
45%
PE:AcOEt 80:20
solid
9h: 6-(3-Hydroxy-



propanol

Rf = 0.05

propyl-amino)-2-







methyl-4-(4,4,4-







trifluoro-butyl)-2H-







[1,2,4]triazine-3,5-







dione


7a
Amino-
34%
CH2Cl2:MeOH
solid
9i: 4-Heptyl-6-(3-



propanol

90:10

hydroxy-propylamino)-





Rf = 0.47

2-methyl-2H-







[1,2,4]triazine-3,5-dione


7b
Amino-
64%
PE:AcOEt 70:30
solid
9j: 4-Heptyl-6-(3-



propanol

Rf = 0.30

hydroxy-propylamino)-







2-(4,4,4-trifluoro-







butyl)-2H-







[1,2,4]triazine-3,5-dione


1b
Amino-
50%
AcOEt
solid
9k: 6-(4-Hydroxy-



butanol

Rf = 0.35

butyl-amino)-2,4-







dimethyl-2H-







[1,2,4]triazine-3,5-dione


7a
Amino-
21%
CH2Cl2:MeOH
solid
9l: 4-Heptyl-6-(4-



butanol

90:10

hydroxy-butylamino)-





Rf = 0.45

2-methyl-2H-







[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck,


PE = petroleum ether






c) 2-heptyl-6-[(3-hydroxy-propyl)-(4,4,4-trifluoro-butyl)-amino]-4-methyl-2H-[1,2,4]triazine-3,5-dione (9m)






7.3 g (24.2 mmol) of triazine 9g are placed in the presence of tert-butyl-chloro-dimethyl-silane (4 g, 26.5 mmol) in 50 ml of dichloromethane at ambient temperature overnight. The reaction medium is then washed with water followed with brine. After drying on MgSO4, the organic phase is dry concentrated and the residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 95:5). 10 g of oil are isolated (quantitative yield). 4.1 g (10 mmol) of this compound are placed in 40 ml of DMF at 0° C. under nitrogen and then 0.4 g (10 mmol) of NaH (60% in paraffin) is added by fractions; this mixture is then stirred for 10 nm. 2.4 g (10 mmol) of 1,1,1-trifluoro-4-iodo-butane are added and the solution is stirred at ambient temperature for 3 h. 0.5 equivalent of NaH as well as 1,1,1-trifluoro-4-iodo-butane are again added and stirring is continued for 2 h. After dry concentration, the residue is taken up in H2O then extracted with AcOEt. After drying on MgSO4, the organic phases are dry concentrated and the oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10). 2 g of compound (yield=40%) are isolated and then diluted in 30 ml of THF; 7.4 ml of a tetrabutylammonium fluoride solution (1 M in THF) is then added dropwise. This mixture is stirred for 2 h at ambient temperature and then 50 ml of water are added and the medium is extracted with AcOEt. After drying on MgSO4, the organic phases are dry concentrated and the oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 70:30). 1.5 g of triazine 9m is this isolated in the form of oil (quantitative yield). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.38.


d) Intermediates 9n-9o






The synthesis of intermediates 9n and 9o is carried out starting from intermediates 9e and 9k, respectively, following the procedure described for the synthesis of 9m using bromoheptane.









TABLE 9







intermediates 9n-9o











Starting






molecule
Yield
TLC
State
Intermediates 9n-9o





9e
59%
heptane:AcOEt
oil
9n: 6-[Heptyl-(3-hydroxy-




50:50

propyl)-amino]-2,4-dimethyl-




Rf = 0.16

2H-[1,2,4]triazine-3,5-






dione


9k
59%
heptane:AcOEt
oil
9o: 6-[Heptyl-(4-hydroxy-




50:50

butyl)-amino]-2,4-dimethyl-




Rf = 0.24

2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






e) 2-heptyl-6-(2-hydroxy-ethoxy)-4-methyl-2H-[1,2,4]triazine-3,5-dione (9p)






1.5 g (4.9 mmol) of triazine 4b and 0.8 g (5.8 mmol) of K2CO3 are placed in 1.5 ml of ethyleneglycol at 130° C. for 0.5 h. 50 ml of water are added to the reaction medium which is then extracted with AcOEt. After drying on MgSO4, the organic phases are dry concentrated and the residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 70:30). 0.5 g of oil corresponding to intermediate 9p is thus isolated (39% yield). TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.08.


f) Intermediates 9q-9s






The synthesis of intermediates 9q-9s is carried out from starting compounds 4b and 1d according to the procedure described for the synthesis of 9p using various diols.









TABLE 10







intermediates 9q-9s












Starting




Intermediates


molecule
Diol
Yield
TLC
State
9q-9s





4b





78%
AcOEtRf = 0.41
oil
9q: 2-Heptyl-6-(3-hydroxy-propoxy)-4-methyl-2H-[1,2,4]triazine-3,5-dione





1d





67%
AcOEtRf = 0.44
oil
9r: 6-(3-Hydroxy-propoxy)-2,4-bis-(4,4,4-trifluoro-butyl)-2H-[1,2,4]triazine-3,5-dione





4b





70%
AcOEtRf = 0.31
oil
9s: 2-Heptyl-6-(4-hydroxy-butoxy)-4-methyl-2H-[1,2,4]triazine-3,5-dione





TLC: silica gel 60 F 254 Merck






Intermediate 10:
a) 3-(2-Hydroxy-ethyl)-phenol (10a)






11.3 g of (3-hydroxy-phenyl)-acetic acid (74.2 mmol) are placed in 100 ml of THF at 0° C. under nitrogen. 100 ml of a solution of LiAlH4 (1 M in THF) is added dropwise at this temperature. The mixture is then placed at 60° C. for 2 h. It is then neutralized slowly with a 6 N HCl solution then extracted with diethyl ether. The organic phases are washed with water, dried on MgSO4, then dry concentrated. The residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 70:30). 9 g of oil corresponding to intermediate 10a are thus isolated (88% yield). TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 70:30, Rf=0.18.


b) Ethyl 2-(3-hydroxy-phenoxy)-2-methyl-propionate (10b)






15 g of resorcinol (136 mmol) are added to 120 ml of a solution of sodium (6.3 g, 274 mmol) in ethanol. The mixture is placed at reflux for 1 h then a solution of ethyl bromoisobutyrate (13.2 ml, 90 mmol) in 30 ml of ethanol is added dropwise. Heating is maintained for 3 h then the reaction medium is dry concentrated. The residue obtained is taken up in a solution of water and acetic acid then extracted with AcOEt. The organic phases are washed with water, dried on MgSO4, then dry concentrated. The residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 90:10). 14.4 g of oil corresponding to intermediate 10b are thus isolated (72% yield). TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 70:30, Rf=0.66.


c) Ethyl 2-(4-hydroxy-phenoxy)-2-methyl-propionate (10c)






11 g of hydroquinone (100 mmol) in 100 ml of DMF is placed at 80° C. for 2 h. This mixture is cooled at ambient temperature then a solution of ethyl bromoisobutyrate (14.7 ml, 100 mmol) in 30 ml of DMF is added dropwise. The mixture is stirred for 3 h then the reaction medium is dry concentrated. The residue obtained is taken up in a 1 N HCl solution then extracted with AcOEt. The organic phases are washed with water, dried on MgSO4, then dry concentrated. The residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 9 g of oil corresponding to intermediate 10c are thus isolated (40% yield). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.50.


d) Ethyl 2-(3-bromo-phenoxy)-2-methyl-propionate (10d)






25 g (144.5 mmol) of 3-bromophenol are placed in the presence of K2CO3 (21 g, 152 mmol) in 75 ml of ethyl 2-bromoisobutyrate and heated to reflux for 7 h. After elimination of K2CO3 by filtration, the reaction medium is dry concentrated. After purification by flash chromatography on silica (petroleum ether:AcOEt 90:10), 37 g of intermediate 10d are collected in the form of clear oil (yield=89%). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.40.


d) Intermediates 10e-10j






The synthesis of intermediates 10e-10j is carried out from the variously substituted phenols listed in table 8 following the procedure described for the synthesis of 10d.









TABLE 11







intermediates 10e-10j











Starting



Intermediates


phenol
Yield
TLC
State
10e-10j



















98%
PE:AcOEt 90:10Rf = 0.52
oil
10e: Ethyl 2-(4-bromo-phenoxy)-2-methyl-propionate










52%
CH2Cl2:AcOEt 80:20Rf = 0.36
oil
10f: Ethyl 2-(4-hydroxymethyl-phenoxy)-2-methyl-propionate










19%
CH2Cl2:AcOEt 90:10Rf = 0.50
oil
10g: Ethyl 2-[2-(2-hydroxy-ethyl)-phenoxy]-2-methyl-propionate





10a
9%
CH2Cl2:
oil
10h: Ethyl 2-[3-(2-




AcOEt 70:30

hydroxy-ethyl)-phe-




Rf = 0.68

noxy]-2-methyl-






propionate










61%
CH2Cl2:AcOEt 90:10Rf = 0.21
oil
10j: Ethyl 2-[4-(2-hydroxy-ethyl)-phe-noxy]-2-methyl-propionate





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 11:
a) Ethyl 2-(3-bromo-phenylsulfanyl)-2-methyl-propionate (11a)






10 g (52.9 mmol) of 3-bromothiophenol are placed in the presence of 9.4 ml (63.5 mmol) of ethyl bromoisobutyrate and 8 g (57.9 mmol) of K2CO3 in 100 ml of EtOH. This mixture is stirred at reflux for 4 h and then dry concentrated. The residue is taken up in water. After extraction in AcOEt and then drying on MgSO4, the organic phases are dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10) and 11a is isolated in the form of clear oil (16.8 g, quantitative yield). TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.72.


c) Intermediates 11b-11e






The synthesis of intermediates 11b-11e is carried out starting from variously substituted thiophenols (G) listed in table 12 following the procedure described for the synthesis of 11a using ethyl or tert-butyl bromoisobutyrate.









TABLE 12







intermediates 11b-11e












Starting thiophenol





Yield
TLC
State
Intermediates 11b-11e










ethylbromoisobutyrate
87%
PE:AcOEt90:10Rf = 0.70
oil
11b: Ethyl 2-(4-bromo-phenylsulfanyl)-2-methyl-propionate










ethylbromoisobutyrate
74%
Heptane:AcOEt80:20Rf = 0.50
oil
11c: Ethyl 2-(3-hydroxy-phenylsul-fanyl)-2-methyl-propionate










ethylbromoisobutyrate
64%
Heptane:AcOEt80:20Rf = 0.20
oil
11d: Ethyl 2-(4-hydroxy-phenylsul-fanyl)-2-methyl-propionate










tert-butylbromoisobutyrate
98%
PE:AcOEt90:10Rf = 0.70
solid
11e: Tert-butyl-2-(4-bromo-phenyl-sulfanyl)-2-methyl-propionate





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 12:
a) Ethyl 2-[3-(3-hydroxy-propyl)-phenoxy]-2-methyl-propionate (12a)






10d (50 g, 175 mmol) is placed in the presence of 2-propynol (12 ml, 210 mmol) in 400 ml of diisopropylamine, under nitrogen. Pd(PPh3)2Cl2 (3.5 g) and CuI (500 mg) are added and the reaction medium is stirred at reflux for 5 h. The precipitate formed in the course of the reaction is filtered on celite and the reaction medium is dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). It is then placed in a solution of 250 ml of THF and 150 ml of EtOH in the presence of Pd/C under hydrogen at 6 bar. This mixture is stirred for 24 h. at ambient temperature. After filtration on celite, the reaction medium is dry concentrated and 12a is isolated in the form of a clear oil (32 g, yield=69%). TLC silica gel 60 F 254 Merck, heptane:AcOEt 80:20, Rf=0.56.


b) Intermediates 12b-12e






The synthesis of intermediates 12b-12e is carried out from the starting bromine compounds listed in table 13 following the procedure described for the synthesis of 12a using various alkynols. Note: in the case of a sulfur derivative, a Wilkinson catalyst is used for the hydrogenation step









TABLE 13







intermediates 12b-12e












Starting







molecule
alkynol
Yield
TLC
State
Intermediates 12b-12d















10d





76%
Heptane:AcOEt60-40Rf = 0.37
oil
12b: Ethyl 2-[3-(5-hydroxy-pentyl)-phenoxy]-2-methyl-propionate





10e





5%
Heptane:AcOEt60-40Rf = 0.33
oil
12c: Ethyl 2-[4-(3-hydroxy-propyl)-phenoxy]-2-methyl-propionate





10e





55%
PE:AcOEt80:20Rf = 0.14
oil
12d: Ethyl 2-[4-(4-hydroxy-butyl)-phenoxy]-2-methyl-propionate





11a





73%
PE:AcOEt70:30Rf = 0.26
oil
12e: Ethyl 2-[3-(3-hydroxy-propyl)-phenylsulfanyl]-2-methyl-propionate





TLC: silica gel 60 F 254 Merck, PE = petroleum ether






Intermediate 13:
a) Ethyl 2-[4-(2-amino-ethyl)-phenoxy]-2-methyl-propionate (13a)






10.1 g (73.6 mmol) of tyramine is placed in the presence of sodium bicarbonate (6.1 g, 72.6 mmol) in a mixture of 100 ml of water and 50 ml of acetone at 0° C. 11.6 ml (81.2 mmol) of benzyl chloroformate is added dropwise at this temperature then the reaction medium is stirred 4 h at ambient temperature. After dry concentration, the residue obtained is taken up in water then extracted with AcOEt. After drying on MgSO4, the organic phases are dry concentrated and the solid obtained is recrystallized in diethyl ether: 17.2 g of solid is thus obtained (86% yield). They are then placed in 37 ml of ethyl bromoisobutyrate in the presence of 8.8 g (63.7 mmol) of potassium carbonate at 130° C. for 5 h. After filtration, the reaction medium is dry concentrated and the residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 70:30). 22.7 g of clear oil are obtained (yield=93%). This oil is then placed in 200 ml of EtOH in the presence of palladium on carbon under, hydrogen at 3 bar and then this solution is stirred for 3 h at ambient temperature. After filtration on celite, the reaction medium is dry concentrated and 14.7 g of intermediate 13a is thus isolated in the form of an oil (quantitative yield). TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 90:10, Rf=0.11.


b) Ethyl 2-[3-(2-amino-ethyl)-phenoxy]-2-methyl-propionate (13b)






10d (14 g, 49 mmol) is placed in the presence of N-vinylphthalimide (11 g, 63 mmol) and 27 ml (194 mmol) of triethylamine in 160 ml of DMF. Pd(OAc)2 (0.3 g) and P(oTol)3 (0.4 g) are added and the reaction medium is stirred for 10 h at 110° C. The reaction medium is dry concentrated and the residue obtained is taken up in water and extracted with AcOEt. After drying on MgSO4, the organic phases are dry concentrated and the oil isolated is purified by flash chromatography on silica (heptane:AcOEt 90:10). 11.5 g of oil is obtained (62% yield) then placed in a solution of 70 ml of THF and 70 ml of EtOH in the presence of Pd/C under hydrogen at 6 bar. This mixture is stirred for 72 h at ambient temperature. After filtration on celite, the reaction medium is dry concentrated and the residue obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 10.9 g of clear oil are obtained (yield=94%). This oil is then placed in 140 ml of EtOH in the presence of 3.5 ml of hydrazine hydrate then this solution is heated at reflux for 4 h. After filtration of the insolubles, the reaction medium is dry concentrated and then the residue obtained is purified by flash chromatography on silica (CH2Cl2:MeOH:NH4OH 90:9:1). 5.7 g of intermediate 13b are thus isolated in the form of an oil (yield=80%). TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH:NH4OH 90:9:1, Rf=0.28.


c) Intermediates 13c-13i






The synthesis of intermediates 13c-13i is carried out from the starting bromine compounds listed in table 14 following the procedure described for the synthesis of 13b using variously N-alkylated phthalimides. (Note: in the case of a sulfur derivative, a Wilkinson catalyst is used for the hydrogenation step









TABLE 14







intermediates 13b-13i












Starting
N-substituted
Total
TLC




molecule
phthalimide
Yield
Form
State
Intermediates 13c-13h





10d
N-
80%
CH2Cl2:MeOH
oil
13c: Ethyl 2-[3-(3-



allylphthalimide

90:10

amino-propyl)-phenoxy]-





Rf = 0.12

2-methyl-







propionate


11a
N-
66%
CH2Cl2:MeOH:NH4OH
oil
13d: Ethyl 2-[3-(2-



vinylphthalimide

90:9:1

amino-ethyl)-phenyl-





Rf = 0.20

sulfanyl]-2-methyl-







propionate


11a
N-
70%
CH2Cl2:MeOH:NH4OH
oil
13e: Ethyl 2-[3-(3-



allylphthalimide

90:9:1

amino-propyl)-





Rf = 0.30

phenylsulfanyl]-2-







methyl-







propionate


11a
N-but-3-enyl-
38%
CH2Cl2:MeOH:NH4OH
oil
13f: Ethyl 2-[3-(4-



phthalimide

90:9:1

amino-butyl)-phenyl-





Rf = 0.27

sulfanyl]-2-methyl-







propionate


11b
N-
41%
CH2Cl2:MeOH:NH4OH
oil
13g: Ethyl 2-[4-(2-



vinylphthalimide

90:9:1

amino-ethyl)-phenyl-





Rf = 0.28

sulfanyl]-2-methyl-







propionate


11b
N-
38%
CH2Cl2:MeOH:NH4OH
oil
13h: Ethyl 2-[4-(3-



allylphthalimide

90:9:1

amino-propyl)-





Rf = 0.23

phenylsulfanyl]-2-







methyl-







propionate


11e
N-
63%
CH2Cl2:MeOH
oil
13i: Tert-butyl 2-



vinylphthalimide

90:10

[4-(2-amino-ethyl)-





Rf = 0.18

phenylsulfanyl]-2-







methyl-propionate





TLC: silica gel 60 F 254 Merck






b) Intermediates 13j-13n






The synthesis of intermediates 13j-13n is carried out from the starting bromine compounds listed in table 15 following the procedures described for the synthesis of 13b using variously N-alkylated phthalimides.









TABLE 15







intermediates 13j-13n












Starting
N-substituted






molecule
phthalimide
Yield
TLC
State
Intermediates 13i-13n










N-allylphthalimide
47%
CH2Cl2:MeOH:NH4OH 80:18:2Rf = 0.25
solid
13j: 3-(3-Amino-propyl)-phenol










N-but-3-enylphthalimide
49%
CH2Cl2:MeOH:NH4OH 80:18:2Rf = 0.24
oil
13k: 3-(4-Amino-butyl)-phenol










N-allylphthalimide
59%
CH2Cl2:MeOH:NH4OH 80:18:2Rf = 0.20
oil
13l: 3-(3-Methoxy-phenyl)-propylamine










N-but-3-enylphthalimide
77%
CH2Cl2:MeOH:NH4OH 80:18:2Rf = 0.28
oil
13m: 4-(3-Methoxy-phenyl)-butylamine










N-pent-4-enyl-phthalimide
24%
CH2Cl2:MeOH:NH4OH 90:9:1Rf = 0.45
oil
13n: 5-(3-Methoxy-phenyl)-pentylamine





TLC: silica gel 60 F 254 Merck






Intermediate 14:
a) Ethyl 2-[4-(2-heptylamino-ethyl)-phenoxy]-2-methyl-propionate (14a)






13a (4.1 g, 5 mmol) is placed in the presence of heptanoic acid (2.3 ml, 16.5 mmol) in 42 ml of dichloromethane. 2.3 ml (16.5 mmol) of triethylamine is added followed by 2.8 ml (18.2 mmol) of diethylcyanophosphonate. This mixture is stirred for 24 h at ambient temperature then the reaction medium is dry concentrated. The residue is taken up in H2O and extracted with ethyl acetate. After drying on MgSO4, the organic phases are dry concentrated and the oil isolated is purified by flash chromatography on silica (CH2Cl2:MeOH 90:10). 4.7 g of oil are obtained (yield=78%). 13 ml of a BH3/THF solution (1 M) is placed at 0° C. under nitrogen then the oil previously obtained, diluted in 20 ml of THF, is added dropwise. This mixture is placed at reflux for 2 h then neutralized by 10 ml of EtOH/HCl (1.5 N). The solution is again placed at reflux for 1 h then dry concentrated. The residue obtained is taken up in a saturated sodium bicarbonate solution then extracted with dichloromethane. After drying on MgSO4, the organic phases are dry concentrated and the oil isolated is purified by flash chromatography on silica (CH2Cl2:MeOH 90:10). 1.6 g of intermediate 14a is thus isolated in the form of an oil (yield=73%). TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH:NH4OH 90:9:1, Rf=0.50.


b) Intermediates 14b-14c






The synthesis of intermediates 14b-14c is carried out starting from intermediate 13a according to the procedure described for the synthesis of 14a using various carboxylic acids.









TABLE 16







intermediates 14b-14c











Carboxylic
Total





acid
yield
Eluent
Form
Intermediates 14b-14c










78%
CH2Cl2:MeOH90:10Rf = 0.37
oil
14b: Ethyl 2-methyl-2-[4-(2-phenethylamino-ethyl)-phenoxy]-propionate










65%
CH2Cl2:MeOH90:10Rf = 0.44
oil
14c: Ethyl 2-methyl-2-{4-[2-(3-phenyl-propylamino)-ethyl]-phenoxy}-propionate





TLC: silica gel 60 F 254 Merck











EXAMPLES
Example 1
Ethyl 2-{2-[2-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (1)






Compound 1 is prepared according to synthesis method 1:1 g (4 mmol) of derivative 10g and 1 g (3.8 mmol) of triazine 5a are placed in 3 ml of DMF in the presence of 0.5 g (3.7 mmol) of K2CO3. This mixture is stirred at 120° C. for 7 h. After filtration and dry concentration of the reaction medium, the residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 98:2). 1.2 g of white crystals are isolated (yield=74%).


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 95:5, Rf=0.40. F=76° C.


RMN 1H (CDCl3): 0.94 ppm (t, 3H, J=7.4 Hz), 1.20 ppm (t, 3H, J=7.2 Hz), 1.39 ppm (m, 2H, J=7.5 ppm), 1.63 ppm (m, 8H), 3.16 ppm (t, 0.2H, J=7.6 Hz), 3.50 ppm (s, 3H), 3.95 ppm (t, 2H, J=7.6 Hz), 4.22 ppm (q, 2H, J=7.0 Hz), 4.37 ppm (t, 2H, J=7.6 Hz), 7.00 ppm (m, 4H).


Example 2
Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (2)






Compound 2 (oil) is prepared from triazine 4b and from intermediate 10h according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.62.


Example 3
Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate (3)






Compound 3 (oil) is prepared from triazine 6a and from intermediate 10h according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.57.


Example 4
Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-propionate (4)






Compound 4 (oil) is prepared from triazine 4a and from intermediate 12a according to synthesis method 1.


TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 70:30, Rf=0.30.


Example 5
Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate (5)






Compound 5 (oil) is prepared from triazine 4b and from intermediate 12a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.52.


Example 6
Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-propionate (6)






Compound 6 (oil) is prepared from triazine 6a and from intermediate 12a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.46.


Example 7
Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate (7)






Compound 7 (oil) is prepared from triazine 7a and from intermediate 12a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.61.


Example 8
Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-2-methyl-propionate (8)






Compound 8 (oil) is prepared from triazine 7b and from intermediate 12a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.53.


Example 9
Ethyl 2-methyl-2-(3-{5-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate (9)






Compound 9 (oil) is prepared from triazine 4a and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254′ Merck, petroleum ether:AcOEt 80:20, Rf=0.34.


Example 10
Ethyl 2-{3-[5-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (10)






Compound 10 (oil) is prepared from triazine 4b and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.54.


Example 11
Ethyl 2-{3-[5-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (11)






Compound 11 (oil) is prepared from triazine 5a and from intermediate 12b according to synthesis method 1.


TLC silica gel 60. F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.29.


Example 12
2-{3-[5-(4-Butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionic Acid (12)






Compound 12 (oil) is prepared by hydrolysis of compound 11 (HCl 12 N, reflux, 16 h, 62%).


TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 90:10, Rf=0.43.


Example 13
Ethyl 2-{3-[5-(2,4-dibutyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (13)






Compound 13 (oil) is prepared from triazine 1c and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.63.


Example 14
Ethyl 2-(3-{5-[4-Butyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate (14)






Compound 14 (oil) is prepared from triazine 5b and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.35.


Example 15
Ethyl 2-{3-[5-(4-butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (15)






Compound 15 (oil) is prepared from triazine 5c and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.


Example 16
Ethyl 2-methyl-2-(3-{5-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate (16)






Compound 16 (oil) is prepared from triazine 6a and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.33.


Example 17
Ethyl 2-{3-[5-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (17)






Compound 17 (oil) is prepared from triazine 7a and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.36.


Example 18
Ethyl 2-(3-{5-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate (18)






Compound 18 (oil) is prepared from triazine 7b and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 70:30, Rf=0.35.


Example 19
Ethyl 2-{3-[5-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate (19)






Compound 19 (oil) is prepared from triazine 7c and from intermediate 12b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.51.


Example 20
Ethyl 2-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate (20)






Compound 20 (oil) is prepared from triazine 4b and from intermediate 10f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.28.


Example 21
Ethyl 2-methyl-2-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-propionate (21)






Compound 21 (oil) is prepared from triazine 6a and from intermediate 10f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 60:40, Rf=0.46.


Example 22
Ethyl 2-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate (22)






Compound 22 (oil) is prepared from triazine 7a and from intermediate 10f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.


Example 23
Ethyl 2-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-2-methyl-propionate (23)






Compound 23 (oil) is prepared from triazine 7b and from intermediate 10f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.61.


Example 24
Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate (24)






Compound 24 (oil) is prepared from triazine 4a and from intermediate 10j according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.45.


Example 25
Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (25)






Compound 25 (oil) is prepared from triazine 4b and from intermediate 10j according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.45.


Example 26
Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate (26)






Compound 26 (oil) is prepared from triazine 7a and from intermediate 10j according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.46.


Example 27
Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate (27)






Compound 27 (oil) is prepared from triazine 4b and from intermediate 12c according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.33.


Example 28
Ethyl 2-methyl-2-(4-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-propionate (28)






Compound 28 (oil) is prepared from triazine 4a and from intermediate 12d according to synthesis method 1.


TLC silica, gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.31.


Example 29
Ethyl 2-{4-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butyl]-phenoxy}-2-methyl-propionate (29)






Compound 29 (oil) is prepared from triazine 4b and from intermediate 12d according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.49.


Example 30
Ethyl 2-methyl-2-(4-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-propionate (30)






Compound 30 (oil) is prepared from triazine 6a and from intermediate 12d according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether AcOEt 70:30, Rf=0.35.


Example 31
Ethyl 2-(4-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-2-methyl-propionate (31)






Compound 31 (oil) is prepared from triazine 7b′ and from intermediate 12d according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.51.


Example 32
Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenylsulfanyl}-2-methyl-propionate (32)






Compound 32 (oil) is prepared from triazine 4b and from intermediate 12e according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.37.


Example 33
Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenoxy}-2-methyl-propionate (33)






Compound 33 is prepared according to synthesis method 2: 1.1 g (3.7 mmol) of triazine 9q, 0.83 g (3.7 mmol) of ester 10b and 1.25 g (4.7 mmol) of PPh3 are placed in 30 ml of THF at 40° C. 0.74 ml (4.7 mmol) of DEAD diluted in 10 ml of THF is added dropwise and the mixture is stirred for 1 h at 40° C. Afterwards, the reaction medium is dry concentrated and the residue obtained is purified by flash chromatography on neutral alumina (heptane:AcOEt 80:20). 0.8 g of compound 33 is isolated in the form of clear oil (yield=43%).


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.30.


Example 34
Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenylsulfanyl}-2-methyl-propionate (34)






Compound 34 (oil) is prepared from triazine 9q and from intermediate 11c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.33.


Example 35
Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate (35)






Compound 35 (oil) is prepared from triazine 9r and from intermediate 10b according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.50.


Example 36
Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenoxy}-2-methyl-propionate (36)






Compound 36 (oil) is prepared from triazine 9s and from intermediate 10b according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.34.


Example 37
Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenylsulfanyl}-2-methyl-propionate (37)






Compound 37 (oil) is prepared from triazine 9s and from intermediate 11c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.37.


Example 38
Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethoxy]-phenylsulfanyl}-2-methyl-propionate (38)






Compound 38 (oil) is prepared from triazine 9p and from intermediate 11d according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.33.


Example 39
Ethyl 2-(4-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate (39)






Compound 39 (oil) is prepared from triazine 9r and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 50:50, Rf=0.50.


Example 40
Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate (40)






Compound 40 (oil) is prepared from triazine 9b and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.29.


Example 41
Ethyl 2-(4-{2-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate (41)






Compound 41 (oil) is prepared from triazine 9a and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.


Example 42
Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate (42)






Compound 42 (oil) is prepared from triazine 9c and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.85.


Example 43
Ethyl 2-(4-{2-[2,4-bis-(3-cyclohexylpropyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate (43)






Compound 43 (oil) is prepared from triazine 9d and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 80:20, Rf=0.85.


Example 44
Ethyl 2-methyl-2-(4-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate (44)






Compound 44 (oil) is prepared from triazine 9f and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.36.


Example 45
Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate (45)






Compound 45 (oil) is prepared from triazine 9g and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.48.


Example 46
Ethyl 2-methyl-2-(4-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate (46)






Compound 46 (solid) is prepared from triazine 9h and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.37. F=116° C.


Example 47
Ethyl 2-{4-[3-(4-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate (47)






Compound 47 (oil) is prepared from triazine 9i and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.30.


Example 48
Ethyl 2-(4-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-2-methyl-propionate (48)






Compound 48 (oil) is prepared from triazine 9j and from intermediate 10c according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.


Example 49
Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenylsulfanyl}-2-methyl-propionate (49)






Compound 49 (oil) is prepared from triazine 9i and from intermediate 11d according to synthesis method 2.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.46.


Example 50
Ethyl 2-{4-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butoxy]-phenoxy}-2-methyl-propionate (50)






Compound 50 (oil) is prepared from triazine 9i and from intermediate 10c according to synthesis method 2.


TLC silica gel 60. F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.


Example 51
Ethyl 2-(3-{3-[(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluoro-butyl)-amino]-propoxy}-phenoxy)-2-methyl-propionate (51)






Compound 51 (oil) is prepared from triazine 9m and from intermediate 10b according to synthesis method 3 using Mitsunobu coupling conditions such as those described for example 33.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 90:10, Rf=0.56.


Example 52
Ethyl 2-(3-{3-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate (52)






Compound 52 (oil) is prepared from triazine 9n and from intermediate 11c according to synthesis method 3 using coupling conditions such as those described for example 33.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 70:30, Rf=0.22.


Example 53
Ethyl 2-(4-{3-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate (53)






Compound 53 (oil) is prepared from triazine 9n and from intermediate 11d according to synthesis method 3 using coupling conditions such as those described for example 33.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 80:20, Rf=0.45.


Example 54
Ethyl 2-(3-{4-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-butoxy}-phenylsulfanyl)-2-methyl-propionate (54)






Compound 54 (oil) is prepared from triazine 9o and from intermediate 11c according to synthesis method 3 using coupling conditions such as those described for example 33.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 70:30, Rf=0.25.


Example 55
Ethyl 2-(2-{2-[3,5-Dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (55)






Compound 55 is prepared according to synthesis method 4: 6.6 g (16.1 mmol) of triazine 1d, 2 g (13.4 mmol) of 2 (2-methoxy-phenyl)-ethylamine and 4.7 ml (33.9 mmol) of triethylamine are placed in 20 ml of n-butanol at 120° C. for 28 h. After dry concentration of the reaction medium, the residue obtained is taken up in H2O and extracted with AcOEt. The organic phases are dried on MgSO4, then dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10). 3.1 g of intermediate are isolated in the form of an oil (yield=48%) which are then placed in 30 ml of CH2Cl2 at 0° C. under nitrogen. A solution of BBr3 (12.8 ml at 1 M in CH2Cl2) is added dropwise and the reaction medium is stirred for 3.5 h at ambient temperature. It is then placed at 0° C. and acidified by a 0.1 N HCl solution until pH=1. The organic phase is decanted and then washed with 100 ml of water. After drying on MgSO4, it is dry concentrated and the residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 95:5). 1.9 g of the corresponding phenol is isolated yield=65%) which is then placed in 2 ml of DMF in the presence of 1.9 ml (12.5 mmol) of ethyl bromoisobutyrate and 0.6 g (4.3 mmol) of K2CO3. The reaction medium is heated at 130° C. for 22 h then filtered and dry concentrated. The oil obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 98:2). 0.8 g of compound 55 (yield=34%) is isolated in the form of an oil.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 95:5, Rf=0.66.


Example 56
Ethyl 2-methyl-2-(3-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate (56)






Compound 56 is prepared according to synthesis method 1: 1.1 g (4.4 mmol) of derivative 13b and 1 g (3.7 mmol) of triazine 4a are placed in 10 ml of nBuOH in the presence of 1.3 ml (9.3 mmol) of triethylamine. This mixture is stirred at 120° C. for 24 h. After dry concentration of the reaction medium, the residue obtained is taken up in H2O and extracted with AcOEt. The organic phases are dried on MgSO4, then dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 90:10). 0.4 g of compound 56 is isolated in the form of an oil (yield=27%).


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.19.


Example 57
Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (57)






Compound 57 (oil) is prepared from triazine 4b and from intermediate 13b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.44.


Example 58
Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate (58)






Compound 58 (oil) is prepared from triazine 6a and from intermediate 13b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.33.


Example 59
Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (59)






Compound 59 (oil) is prepared from triazine 7a and from intermediate 13b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.


Example 60
Ethyl 2-(3-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (60)






Compound 60 (oil) is prepared from triazine 7b and from intermediate 13b according to synthesis method 1.


TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 90:10, Rf=0.22.


Example 61
Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate (61)






Compound 61 (oil) is prepared from triazine 7a and from intermediate 13d according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.61.


Example 62
Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-propionate (62)






Compound 62 (oil) is prepared from triazine 4a and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.60.


Example 63
Ethyl 2-(3-{3-[2-(2-cyano-ethyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (63)






Compound 63 (oil) is prepared from triazine 3a and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.44.


Example 64
Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (64)






Compound 64 (oil) is prepared from triazine 4b and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.20.


Example 65
Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-propionate (65).






Compound 65 (oil) is prepared from triazine 6a and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.78.


Example 66
Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (66)






Compound 66 (oil) is prepared from triazine 1d and from intermediate 131 according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.49.


Example 67
Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (67)






Compound 67 (oil) is prepared from triazine 7a and from intermediate 13c according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.


Example 68
Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (68)






Compound 68 (oil) is prepared from triazine 7b and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.63.


Example 69
Ethyl 2-{3-[3-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (69)






Compound 69 (oil) is prepared from triazine 1e and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.


Example 70
Ethyl 2-{3-[3-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (70)






Compound 70 (oil) is prepared from triazine 7c and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.47.


Example 71
Ethyl 2-(3-{3-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate (71)






Compound 71 (oil) is prepared from triazine 8a and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.30.


Example 72
Ethyl 2-{3-[3-(4-Benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate (72)






Compound 72 (oil) is prepared from triazine 8b and from intermediate 13j according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.42.


Example 73
Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenylsulfanyl}-2-methyl-propionate (73)






Compound 73 (oil) is prepared from triazine 7a and from intermediate 13e according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.58.


Example 74
Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (74)






Compound 74 (oil) is prepared from triazine 4a and from intermediate 13m according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.21.


Example 75
Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (75)






Compound 75 (oil) is prepared from triazine 4b and from intermediate 13m according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.44.


Example 76
Ethyl 2-methyl-2-(3-{4-[4-(3-methyl-but-2-enyl)-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (76)






Compound 76 (oil) is prepared from triazine 5d and from intermediate 13m according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.50.


Example 77
Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (77)






Compound 77 (oil) is prepared from triazine 6a and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.35.


Example 78
Tert-butyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate (78)






Compound 78 (oil) is prepared from triazine 6a and from intermediate 13m according to synthesis method 4 using tert-butyl bromoisobutyrate in the last step.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 60:40, Rf=0.35.


Example 79
2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionic Acid (79)






After the hydrolysis of compound 78 (trifluoroacetic acid/CH2Cl2, yield=61%), compound 79 is isolated in the form of a solid.


TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 90:10, Rf=0.73. F=116° C.


Example 80
Ethyl 2-(3-{4-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (80)






Compound 80 (oil) is prepared from triazine 1d and from intermediate 13m according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.32.


Example 81
Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (81)






Compound 81 (oil) is prepared from triazine 3b and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.20.


Example 82
Ethyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (82)






Compound 82 (oil) is prepared from triazine 6b and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.37.


Example 83
Tert-butyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (83)






Compound 83 (oil) is prepared from triazine 6b and from intermediate 13m according to synthesis method 4 using tert-butyl bromoisobutyrate in the last step.


TLC silica gel 60 F 254 Merck, heptane:AcOEt 60:40, Rf=0.43.


Example 84
2-(3-{4-[2-Heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionic Acid (84)






After the hydrolysis of compound 83 (trifluoroacetic acid/CH2Cl2, yield=76%), compound 84 is isolated in the form of an oil.


TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 95:5, Rf=0.39.


Example 85
Ethyl 2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (85)






Compound 85 (oil) is prepared from triazine 7b and from intermediate 13m according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.75.


Example 86
Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (86)






Compound 86 (oil) is prepared from triazine 3c and from intermediate 13m according to synthesis method 4.


TLC silica gel 60 F 254. Merck, petroleum ether:AcOEt 70:30, Rf=0.51.


Example 87
Ethyl 4-(6-{4-[3-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-butylamino}-4-heptyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-but-2-enonate (87)






Compound 87 (oil) is prepared according to synthesis method 6: 0.2 g (5 mmol) of NaH (60% in paraffin) is placed in suspension in 10 ml of DMF at 0° C. under nitrogen. 1.4 g (2.6 mmol) of compound 86 diluted in 4 ml of DMF is added dropwise. The mixture is stirred for 4.5 h at ambient temperature then dry concentrated. The residue is taken up in H2O and extracted with AcOEt. The organic phases are dried on MgSO4, then dry concentrated. The oil obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 90:10) and 0.8 g of solid is isolated (yield=63%). 78 mg (1.9 mmol) of NaH (60% in paraffin) is placed in suspension in 15 ml of DMF at 0° C. under nitrogen. The solid previously isolated (0.8 g, 1.6 mmol) diluted in 5 ml of DMF is added dropwise then this mixture is stirred for 1 h at ambient temperature. 0.29 ml (2.1 mmol) of ethyl 4-bromo-but-2-enoate is added and then stirring is continued for 9 h. After dry concentration, the residue obtained is taken up in H2O and extracted with AcOEt. The organic phases are dried on MgSO4, then dry concentrated. The oil obtained is purified by flash chromatography on silica (petroleum ether:AcOEt 80:20). 0.6 g of compound 87 is isolated in the form of an oil (yield=56%).


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.33.


Example 88
Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (88)






Compound 88 (oil) is prepared from triazine 1e and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.


Example 89
Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (89)






Compound 89 (solid) is prepared from triazine 7c and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.37. F=58° C.


Example 90
Ethyl 2-(3-{3-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate (90)






Compound 90 (oil) is prepared from triazine 8a and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.46.


Example 91
Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate (91)






Compound 91 (oil) is prepared from triazine 8b and from intermediate 13k according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.60.


Example 92
Ethyl 2-(3-{5-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-pentyl}-phenoxy)-2-methyl-propionate (92)






Compound 92 (oil) is prepared from triazine 1d and from intermediate 13n according to synthesis method 4.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.45.


Example 93
Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionate (93)






Compound 93 (oil) is prepared from triazine 4a and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20; Rf=0.45.


Example 94
Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (94)






Compound 94 (oil) is prepared from triazine 4b and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.26.


Example 95
Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl)}-phenylsulfanyl)-propionate (95)






Compound 95 (oil) is prepared from triazine 6a and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 2.54 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.


Example 96
2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionic Acid (96)






After the hydrolysis of compound 95 (BBr3/CH2Cl2, yield=49%), compound 96 is isolated in the form of a solid.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 80:20, Rf=0.24. F=106° C.


Example 97
Ethyl 2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate (97)






Compound 97 (oil) is prepared from triazine 7b and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.74.


Example 98
Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (98)






Compound 98 (oil) is prepared from triazine 1e and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.53.


Example 99
Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (99)






Compound 99 (oil) is prepared from triazine 7c and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.43.


Example 100
Ethyl 2-(3-{4-[4-Benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate (100)






Compound 100 (oil) is prepared from triazine 8a and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.27.


Example 101
Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate (101)






Compound 101 (oil) is prepared from triazine 8b and from intermediate 13f according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.39.


Example 102
Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate (102)






Compound 102 (oil) is prepared from triazine 4a and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.22.


Example 103
Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (103)






Compound 103 (oil) is prepared from triazine 4b and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.54.


Example 104
Ethyl 4-[6-{2-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-ethylamino}-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-but-2-enoate (104)






Compound 104 (oil) is prepared from triazine 3b and from intermediate 13a according to synthesis method 6 with ethyl 4-bromo-but-2-enoate used in the alkylation step.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.


Example 105
Ethyl 2-(4-{2-[2-(3-cyclohexyl-propyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (105)






Compound 105 (oil) is prepared from triazine 6c and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.44.


Example 106
Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (106)






Compound 106 (solid) is prepared from triazine 7a and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 70:30, Rf=0.60. F=54° C.


Example 107
Ethyl 2-(4-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate (107)






Compound 107 (solid) is prepared from triazine 7b and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.47. F=63° C.


Example 108
Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (108)






Compound 108 (oil) is prepared from triazine 1e and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.57.


Example 109
Ethyl 2-{4-[2-(4 benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate (109)






Compound 109 (solid) is prepared from triazine 8b and from intermediate 13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.60. F=65° C.


Example 110
Ethyl 2-{4-[2-(2,4-bis-benzyloxymethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)ethyl]-phenoxy}-2-methyl-propionate (110)






Compound 110 (oil) is prepared from triazine 1g and from intermediate-13a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.34.


Example 111
Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluoro-butyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate (111)






Compound 111 is prepared according to synthesis method 5: 3.2 g (14.7 mmol) of triazine 1b and 5.4 ml (36.8 mmol) of 2-(4-methoxy-phenyl)-ethylamine are placed in 30 ml of nBuOH in the presence of 5.1 ml (36.8 mmol) of triethylamine at 130° C. for 10.5 h. After dry concentration, the residue obtained is taken up in H2O and extracted with AcOEt. The organic phases are dried on MgSO4, then dry concentrated. The oil obtained is purified by flash chromatography on silica (heptane:AcOEt 50:50) and 2.3 g of solid is isolated (yield=54%). 0.48 g (12 mmol) of NaH (60% in paraffin) is placed in suspension in 15 ml of DMF at 0° C. under nitrogen. 2.3 g (7.9 mmol) of the previously isolated solid diluted in 5 ml of DMF are added dropwise. The mixture is stirred for 0.5 h at ambient temperature and then 4.7 g (19.8 mmol) of 1,1,1-trifluoro-4-iodo-butane are added and stirring is continued for 6.5 h. After dry concentration, the residue obtained is taken up in H2O and extracted with AcOEt. The organic phases are dried on MgSO4, then dry concentrated. The oil obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 95:5) and 0.82 g of oil is isolated (yield=26%). 0.4 g of the latter is then placed in 15 ml of CH2Cl2 at −60° C. under nitrogen, a BBr3 solution (1 M in CH2Cl) (0.24 ml diluted in 2 ml of CH2Cl2) is added dropwise and the reaction medium is stirred for 2 h at ambient temperature It is next placed at 0° C. and neutralized by a 1 N HCl solution. The organic phase is decanted and then washed with 100 ml of water. After drying on MgSO4, it is dry concentrated and 0.38 g of the corresponding phenol is isolated (quantitative yield). It is then placed in 0.5 ml of ethyl bromoisobutyrate in the presence of 0.14 g (1 mmol) of K2CO3 at 150° C. for 5 h. After filtration and dry concentration, the residue obtained is purified by flash chromatography on silica (CH2Cl2:AcOEt 95:5) and 0.25 g of compound 111 is isolated in the form of an oil (yield=51%).


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.65.


Example 112
Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionate (112)






Compound 112 (oil) is prepared from triazine 1b and from intermediate 14a according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 70:30, Rf=0.70.


Example 113
2-(4-{2-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionic Acid (113)






Compound 113 is prepared from triazine 1b and from 2-(4-methoxy-phenyl)-ethylamine according to synthesis method 5 by alkylating nitrogen with 1-bromoheptane and by using tert-butyl bromoisobutyrate. After hydrolysis with trifluoroacetic acid in CH2Cl2, compound 113 is isolated in the form of oil.


TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 90:10, Rf=0.43.


Example 114
Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate (114)






Compound 114 (oil) is prepared from triazine 1b and from intermediate 14b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.74.


Example 115
Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenylpropyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate (115)






Compound 115 (oil) is prepared from triazine 1b and from intermediate 14c according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2:AcOEt 90:10, Rf=0.63.


Example 116
Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate (116)






Compound 116 (oil) is prepared from triazine 7a and from intermediate 14b according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2, Rf=0.52.


Example 117
Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate (117)






Compound 117 (oil) is prepared from triazine 7a and from intermediate 14c according to synthesis method 1.


TLC silica gel 60 F 254 Merck, CH2Cl2, Rf=0.46.


Example 118
2-Methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-propionic Acid (118)






Compound 118 is prepared from triazine 4a and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH2Cl2, compound 118 is isolated in the form of a solid.


TLC silica gel 60 F 254 Merck, AcOEt, Rf=0.42. F=128° C.


Example 119
Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate (119)






Compound 119 (oil) is prepared from triazine 4b and from intermediate 13g according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.60.


Example 120
2-{4-[2-(2-Heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic Acid (120)






Compound 120 is prepared from triazine 4b and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH2Cl2, compound 120 is isolated in the form of a solid.


TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 90:10, Rf=0.34. F=70° C.


Example 121
2-{4-[2-(4-Butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic Acid (121)






Compound 121 is prepared from triazine 5c and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH2Cl2, compound 121 is isolated in the form of oil.


TLC silica gel 60 F 254 Merck, CH2Cl2:MeOH 98:2, Rf=0.46.


Example 122
Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate (122)






Compound 122 (solid) is prepared from triazine 7a and from intermediate 13g according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.67. F=49° C.


Example 123
2-(4-{2-[4-Heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-2-methyl-propionic Acid (123)






Compound 123 is prepared from triazine 7b and from intermediate 13i according to synthesis method 1. After hydrolysis with trifluoroacetic acid in CH2Cl2, compound 123 is isolated in the form of a solid.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.19. F=86° C.


Example 124
Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)propyl]-phenylsulfanyl}-2-methyl-propionate (124)






Compound 125 (oil) is prepared from triazine 4b and from intermediate 13h according to synthesis method 1.


TLC silica gel 60 F 254 Merck, petroleum ether:AcOEt 80:20, Rf=0.20.


Pharmacological Evaluation

In Vitro


Activation of transcription (transactivation) of the reporter gene controlled by specific response elements after binding of the ligand to the receptor (reporter gene assay).


These experiments were carried out according to J. M. Lehmann et al. (J. Biol. Chem. 1995, 270:12953-12956) with several modifications. Subconfluent Cos-7 cells (ATCC, CRL-1651) were transfected with (i) chimeric receptors containing the binding domain for human PPARα or PPARγ or PPARδ ligand bound to the DNA binding domain of yeast galactosidase (Gal-4), and (ii) the reporter plasmid containing five copies of the Gal-4 response element upstream of the thymidine kinase promoter adjacent to the luciferase gene (p5xUAS-tk-Luc). After 24 hours, these cells were treated for the following 24 hours by compounds and their vehicle and luciferase activity were evaluated after cellular extraction according to the manufacturer's (Promega) recommendations.


The results are reported in table 17 below, in which the designation “hit” indicates a compound whose transactivation level is significant but for which definition of an EC50 is not possible, and in which the designation “nd” indicates that no data was collected.









TABLE 17







reporter gene transactivation by various human PPAR subtypes











hPPAR-
hPPAR-
hPPAR-



GAL4 alpha
GAL4 gamma
GAL4 delta


Examples
EC50 (μM)
EC50 (μM)
EC50 (μM)













Fenofibric
16.9
65.2
>100


acid





Rosiglitazone
0
1.12
0


Pioglitazone
>10
4.77
0


1
 3-10
0
0


2
>10
~10
0


3
~3
0
0


4
>10
0
0


5
~3
~10
0


6
~0.3
0
0


7
0.3-1  
1-3 
0


8
~0.3
3-10
0


9
3-10
~10
0


10
0.3-1  
~1
0


11
0.3-1  
1-3 
0


12
~0.03
1-3 
hit


13
0.01-0.03
0.1-0.3 
~3


14
0.01-0.03
~1
~10


15
0.001-0.003
0.1-0.3 
hit


16
~0.1
3-10
0


17
0.3-1  
~0.3
0


18
0.03-0.1 
~1
0


19
~3
3-10
0


20
hit
hit
0


21
 3-10
0
0


22
10
hit
0


23
1
hit
0


24
>10
0
0


25
hit
>10
hit


26
>10
0
0


27
~3
3-10
3-10


28
~10
hit
0


29
 3-10
3-10
3-10


30
0.03-0.1 
>10
hit


31
~0.1
~1
3-10


32
1-3
hit
0


33
~3
~3
0


34
>10
>10
0


35
0.03-0.1 
3-10
~10


36
0.3-1  
3-10
hit


37
>10
~10
0


38
>10
>10
0


39
0.1-0.3
3-10
~3


40
 3-10
~10
>10


41
~0.1
~10
1-3 


42
~1
>10
1-3 


43
~3
hit
0


44
>10
3-10
0


45
1-3
~3
hit


46
0.3-1  
0
0


47
~0.3
~0.3
hit


48
0.3-1  
0.3-1  
~3


49
>10
>10
0


50
>10
~10
0


51
 3-10
>10
0


52
hit
0
0


53
1-3
0
0


54
>10
0
0


55
>10
0
0


56
hit
hit
0


57
~3
1-3 
hit


58
>10
0
0


59
1-3
nd
0


60
>10
hit
0


61
~3
nd
0


62
>10
0
0


63
0
hit
0


64
>10
3-10
hit


65
0.1-0.3
>10
0


66
0.03-0.1 
>10
~10


67
~1
nd
0


68
0.1-0.3
3-10
0


69
1-3
~10
0


70
~1
~10
0


71
~1
hit
0


72
 3-10
3-10
0


73
0.1-0.3
nd
0


74
~1
3-10
0


75
 3-10
3-10
0


76
0.01-0.03
1-3 
3-10


77
~0.3
3-10
0


78
>10
0
0


79
~0.03
3-10
0


80
0.01-0.03
0.3-1  
>10


81
0.3-1  
>10
0


82
~0.01
0.1-0.3 
hit


83
>10
0
0


84
0.003-0.01 
~0.3
1-3 


85
~0.03
1-3 
hit


86
>10
~1
hit


87
~0.3
0.1-0.3 
hit


88
~0.3
~10
0


89
>10
1-3 
3-10


90
~0.1
~10
0


91
0.3-1  
3-10
0


92
0.003-0.01 
3-10
0


93
>10
hit
0


94
 3-10
3-10
0


95
1-3
>10
0


96
0.03-0.1 
~10
>10


97
1-3
hit
0


98
>10
0
0


99
>10
3-10
0


100
1-3
>10
0


101
1-3
0
0


102
>10
hit
0


104
1-3
>10
0


105
1-3
~10
0


106
~1
nd
>10


107
~1
hit
0


108
>10
hit
0


109
~1
nd
3-10


110
1-3
hit
>10


111
0
hit
0


112
1-3
~10
1-3 


113
0.3-1  
3-10
0.3-1  


114
~10
nd
0


115
~3
nd
>10


116
~10
nd
0


117
~10
nd
0


118
1-3
~10
0


119
0.3
0.3
hit


120
0.3-1  
1-3 
hit


121
0.03-0.1 
1-3 
hit


122
~0.3
nd
>10


123
0.1-0.3
~10
0


124
0.3-1  
>10
0









In Vivo


Normalization of metabolic parameters (cholesterol, plasma triglycerides) in an insulinresistant male rat (Ico: ZUCKER-fa/fa), unfed for 16-18 hours, after treatment by oral route, once per day for four days, with the compounds to be evaluated or their administration vehicle.


These metabolic parameters are measured by spectrophotometry at the beginning and the end of each animal's treatment.









TABLE 18







Normalization of metabolic parameters










Plasma
Plasma


Examples
triglycerides
cholesterol












11
inactive at 2.5
−25% at 2.5 mg/kg



mg/kg
−25% at 10 mg/kg



−37% at 10 mg/kg


13
inactive at 2.5
−8% at 2.5 mg/kg



mg/kg
−12% at 10 mg/kg



−28% at 10 mg/kg


15
−22% at 2.5 mg/kg
−4% at 2.5 mg/kg



−63% at 10 mg/kg
−8% at 10 mg/kg


16
inactive at 2.5
−14% at 2.5 mg/kg



mg/kg
−25% at 10 mg/kg



−15% at 10 mg/kg


17
−37% at 10 mg/kg
active at 10




mg/kg


41
inactive at 10
−28% at 10 mg/kg



mg/kg


45
inactive at 10
−16% at 10 mg/kg



mg/kg


46
−32% at 10 mg/kg
−13% at 10 mg/kg


47
−45% at 10 mg/kg
−25% at 10 mg/kg


53
inactive at 10
−7% at 2.5 mg/kg



mg/kg
−28% at 10 mg/kg


59
−13% at 2.5 mg/kg
−37% at 2.5 mg/kg


65
inactive at 2.5
−13% at 2.5 mg/kg



mg/kg
−23% at 10 mg/kg



−13% at 10 mg/kg


66
inactive at 10
−9% at 10 mg/kg



mg/kg


67
−23% at 10 mg/kg
−14% at 10 mg/kg


68
active at 10 mg/kg
−21% at 10 mg/kg


72
inactive at 10
−21% at 10 mg/kg



mg/kg


73
inactive at 10
−14% at 10 mg/kg



mg/kg


74
inactive at 2.5
−18% at 2.5 mg/kg



mg/kg
−29% at 10 mg/kg



−26% at 10 mg/kg


75
active at 10
−19% at 2.5 mg/kg



mg/kg
−13% at 10 mg/kg


76
−7% at 10 mg/kg
−16% at 2.5 mg/kg




−22% at 10 mg/kg


77
active at 10 mg/kg
−29% at 2.5 mg/kg




−35% at 10 mg/kg


79
−55% at 2.5 mg/kg
−32% at 2.5 mg/kg


80
inactive at 10
−16% at 10 mg/kg



mg/kg


81
−17% at 10 mg/kg
−12% at 10 mg/kg


82
active at 10 mg/kg
−13% at 10 mg/kg


84
inactive at 2.5
inactive at 2.5



mg/kg
mg/kg



−7% at 10 mg/kg
−13% at 10 mg/kg


85
active at 10 mg/kg
−21% at 10 mg/kg


92
inactive at 10
−18% at 10 mg/kg



mg/kg


95
inactive at .10
−18% at 2.5 mg/kg



mg/kg
−40% at 10 mg/kg


96
−26% at 2.5 mg/kg
−28% at 2.5 mg/kg



−60% at 10 mg/kg
−21% at 10 mg/kg


112
−31% at 10 mg/kg
−43% at 10 mg/kg


113
inactive at 2.5
−30% at 2.5 mg/kg



mg/kg
−40% at 10 mg/kg



−26% at 10 mg/kg


119
active at 2.5
−21% at 2.5 mg/kg



mg/kg
−32% at 10 mg/kg



−29% at 10 mg/kg


120
−27% at 2.5 mg/kg
−32% at 2.5 mg/kg



−73% at 10 mg/kg
−33% at 10 mg/kg


121
−24% at 2.5 mg/kg
−7% at 2.5 mg/kg


122
−35% at 10 mg/kg
−22% at 10 mg/kg


123
−6% at 2.5 mg/kg
−8% at 2.5 mg/kg



−20% at 10 mg/kg
−14% at 10 mg/kg









Thus, the present invention relates to the compounds of formula I previously defined as novel medicines of use in the treatment of diseases requiring PPAR alpha and/or PPAR gamma receptor agonists. These compounds are of use in the prevention and the treatment of diseases such as diabetic dyslipidemia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, and in dermatology in pathologies with an inflammatory component or resulting from abnormal cell differentiation as well as in the treatment of diseases such as psoriasis, acne, atopic dermatitis, cutaneous aging and photoaging.


Lastly, the invention relates to pharmaceutical compounds containing as an active ingredient at least one compound of formula I previously defined, preferably in association with a suitable excipient.

Claims
  • 1) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I
  • 2) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I according to claim 1 in which: R1 and R2 represent, independently one from the other, an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl, cycloalkyl at C6, nitrile, or phenyl (for which the core phenyl is possibly substituted by one or more groups such as alkyl at C1-C4, alkoxy at C1-C4, nitro, halogen or trifluoromethyl),YR3 represents oxygen or NR3 in which R3 represents hydrogen, an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl or phenyl,Z represents an oxygen atom or a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula In can range from 0 to 5 when Z=C or from 2 to 4 when Z=O,X represents oxygen or sulfur,R4, R5, R6, R7 and R8 represent hydrogen or fluorine,R9, R10 and R11 represent hydrogen or an alkyl group, linear or branched, at C1-C5.
  • 3) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I according to one of the claims 1 and 2 in which: R1 and R2 represent independently one from the other, an alkyl or alkenyl radical, linear or branched, at C1-C7, an alkyl radical at C1-C6 substituted by groups such as trifluoromethyl or nitrile,YR3 represents oxygen or NR3 in which R3 represents hydrogen or a linear or branched alkyl radical at C1-C7,Z represents a carbon atom which can be bound in ortho, meta or para position on the phenyl group of formula I,n can range from 0 to 5,X represents oxygen or sulfur,R4, R5, R6, R7 and R8 represent hydrogen or fluorine,R9, R10 and R11 represents hydrogen or a linear or branched alkyl group at C1-C5, in particular R9 and R10 represent a methyl group and R11 hydrogen or an ethyl group.
  • 4) 3,5-Dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula I according to one of the claims 1 and 3 in which: R1 and R2 represent independently one from the other, an alkyl or alkenyl radical, linear or branched, at C1-C7, possibly substituted at the end of the chain by a trifluoromethyl group,YR3 represents oxygen or NR3 in which R3 represents hydrogen or a linear or branched alkyl radical at C1-C7,Z represents a carbon atom which can be bound in meta or para position on the phenyl group of formula I,n can range from 1 to 5,X represents oxygen or sulfur,R4 to R8 represent hydrogen,R9 and R10 represent a methyl radicalR11 represents hydrogen or an ethyl radical.
  • 5) Compounds of general formula I according to claim 1) wherein they are selected among: 1. Ethyl 2-{2-[2-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate2. Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate3. Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate4. Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate5. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate6. Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate7. Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate8. Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propyl}-phenoxy)-2-methyl-propionate9. Ethyl 2-methyl-2-(3-{5-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate10. Ethyl 2-{3-[5-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate11. Ethyl 2-{3-[5-(4-butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate12. 2-{3-[5-(4-Butyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionic acid13. Ethyl 2-{3-[5-(2,4-dibutyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate14. Ethyl 2-(3-{5-[4-butyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate15. Ethyl 2-{3-[5-(4-butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate16. Ethyl 2-methyl-2-(3-{5-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-propionate17. Ethyl 2-{3-[5-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl propionate18. Ethyl 2-(3-{5-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-pentyl}-phenoxy)-2-methyl-propionate19. Ethyl 2-{3-[5-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-pentyl]-phenoxy}-2-methyl-propionate20. Ethyl-2-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate21. Ethyl 2-methyl-2-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-propionate22. Ethyl 2-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl)-phenoxy]-2-methyl-propionate23. Ethyl 2-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxymethyl]-phenoxy}-2-methyl-propionate24. Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate25. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate26. Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate27. Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenoxy}-2-methyl-propionate28. Ethyl 2-methyl-2-(4-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate29. Ethyl 2-{4-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethyl]-phenoxy}-2-methyl-propionate30. Ethyl 2-methyl-2-(4-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-ethyl}-phenoxy)-propionate31. Ethyl 2-(4-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-butyl}-phenoxy)-2-methyl-propionate32. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propyl]-phenylsulfanyl}-2-methyl-propionate33. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenoxy}-2-methyl-propionate34. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-propoxy]-phenylsulfanyl}-2-methyl-propionate35. Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate36. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenoxy}-2-methyl-propionate37. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-butoxy]-phenylsulfanyl}-2-methyl-propionate38. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy)-ethoxy]-phenylsulfanyl}-2-methyl-propionate39. Ethyl 2-(4-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yloxy]-propoxy}-phenoxy)-2-methyl-propionate40. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate41. Ethyl 2-(4-{2-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate42. Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethoxy]-phenoxy}-2-methyl-propionate43. Ethyl 2-(4-{2-[2,4-bis-(3-cyclohexyl-propyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethoxy}-phenoxy)-2-methyl-propionate44. Ethyl 2-methyl-2-(4-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate45. Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate46. Ethyl 2-methyl-2-(4-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-propionate47. Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenoxy}-2-methyl-propionate48. Ethyl 2-(4-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propoxy}-phenoxy)-2-methyl-propionate49. Ethyl 2-{4-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propoxy]-phenylsulfanyl}-2-methyl-propionate50. Ethyl 2-{4-[4-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butoxy]-phenoxy}-2-methyl-propionate51. Ethyl 2-(3-{3-[(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluoro-butyl)-amino]-propoxy}-phenoxy)-2-methyl-propionate52. Ethyl 2-(3-{3-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate53. Ethyl 2-(4-{3-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-propoxy}-phenylsulfanyl)-2-methyl-propionate54. Ethyl 2-(3-{4-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-butoxy}-phenylsulfanyl)-2-methyl-propionate55. Ethyl 2-(2-{2-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate56. Ethyl 2-methyl-2-(3-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate57. Ethyl 2-{3-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate58. Ethyl 2-methyl-2-(3-{2-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate59. Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate60. Ethyl 2-(3-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate61. Ethyl 2-{3-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate62. Ethyl 2-methyl-2-(3-{3-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate63. Ethyl 2-(3-{3-[2-(2-cyano-ethyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate64. Ethyl 2-{3-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate65. Ethyl 2-methyl-2-(3-{3-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate66. Ethyl 2-(3-{3-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate67. Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate68. Ethyl 2-(3-{3-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate69. Ethyl 2-{3-[3-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate70. Ethyl 2-{3-[3-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate71. Ethyl 2-(3-{3-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-propyl}-phenoxy)-2-methyl-propionate72. Ethyl 2-{3-[3-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenoxy}-2-methyl-propionate73. Ethyl 2-{3-[3-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenylsulfanyl}-2-methyl-propionate74. Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate75. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate76. Ethyl 2-methyl-2-(3-{4-[4-(3-methyl-but-2-enyl)-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate77. Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate78. Tert-butyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionate79. 2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-propionic acid80. Ethyl 2-(3-{4-[3,5-dioxo-2,4-bis-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate81. Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate82. Ethyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate83. Tert-butyl 2-(3-{4-[2-heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate84. 2-(3-{4-[2-Heptyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl)}-phenoxy)-2-methyl-propionic acid85. Ethyl 2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate86. Ethyl 2-(3-{4-[2-(2-cyano-ethyl)-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate87. Ethyl 4-(6-{4-[3-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-butylamino}-4-heptyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-but-2-enonate88. Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate89. Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate90. Ethyl 2-(3-{4-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenoxy)-2-methyl-propionate91. Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenoxy}-2-methyl-propionate92. Ethyl 2-(3-{5-[3,5-dioxo-2,4-bis-(4,4,4-trifluorobutyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-pentyl}-phenoxy)-2-methyl-propionate93. Ethyl 2-methyl-2-(3-{4-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionate94. Ethyl 2-{3-[4-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate95. Ethyl 2-methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionate96. 2-Methyl-2-(3-{4-[2-methyl-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-propionic acid97. Ethyl-2-(3-{4-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate98. Ethyl 2-{3-[4-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate99. Ethyl 2-{3-[4-(2-benzyl-4-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate100. Ethyl 2-(3-{4-[4-benzyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-butyl}-phenylsulfanyl)-2-methyl-propionate101. Ethyl 2-{3-[4-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-butyl]-phenylsulfanyl}-2-methyl-propionate102. Ethyl 2-methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate103. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate104. Ethyl 4-[6-{2-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenyl]-ethylamino}-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-but-2-enoate105. Ethyl 2-(4-{2-[2-(3-cyclohexyl-propyl)-3,5-dioxo-4-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4,5]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate106. Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate107. Ethyl 2-(4-{2-[4-heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-2-methyl-propionate108. Ethyl 2-{4-[2-(2,4-diheptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate109. Ethyl 2-{4-[2-(4-benzyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)ethyl]-phenoxy}-2-methyl-propionate.110. Ethyl 2-{4-[2-(2,4-bis-benzyloxymethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenoxy}-2-methyl-propionate111. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(4,4,4-trifluorobutyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate112. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionate113. 2-(4-{2-[(2,4-Dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-heptyl-amino]-ethyl}-phenoxy)-2-methyl-propionic acid114. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate115. Ethyl 2-(4-{2-[(2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate116. Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-phenethyl-amino]-ethyl}-phenoxy)-2-methyl-propionate117. Ethyl 2-(4-{2-[(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-yl)-(3-phenyl-propyl)-amino]-ethyl}-phenoxy)-2-methyl-propionate118. 2-Methyl-2-(4-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-propionic acid119. Ethyl 2-{4-[2-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)ethyl]-phenylsulfanyl}-2-methyl-propionate120. 2-{4-[2-(2-Heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic acid121. 2-{4-[2-(4-Butyl-2-heptyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionic acid122. Ethyl 2-{4-[2-(4-heptyl-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-ethyl]-phenylsulfanyl}-2-methyl-propionate123. 2-(4-{2-[4-Heptyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenylsulfanyl)-2-methyl-propionic acid124. Ethyl 2-{4-[3-(2-heptyl-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino)-propyl]-phenylsulfanyl}-2-methyl-propionate
  • 6) Method of preparation of the chemical compounds according to one of the claims 1) to 5) wherein: a derivative of general formula II is condensed
  • 7) Method of preparation according to one of the claims 1) to 5) of the chemical compounds of general formula I in which Z=O wherein: a) a derivative of general formula II is condensed
  • 8) Method of preparation according to one of the claims 1) to 5) of the chemical compounds of general formula I in which Z=O wherein: a) the alcohol function of a derivative of general formula VII is protected
  • 9) Method of preparation of chemical compounds of general formula I according to one of the claims 1) to 5) when Y═N and which Z=C wherein: a) a derivative of general formula II is condensed
  • 10) Method of preparation of chemical compounds of general formula I, according to one of the claims 1) to 5) when Y═N and Z=C wherein: a) a derivative of general formula XIV is alkylated
  • 11) Method of preparation of the chemical compounds according to one of the claims 1) to 5) wherein: a) a derivative of general formula I is placed
  • 12) As novel medicines of use in the treatment of disorders requiring PPAR alpha and/or PPAR gamma receptor agonists, the compounds defined according to one of the claims 1) to 5).
  • 13) As novel medicines of use in the prevention and the treatment of diseases such as diabetic dyslipidemia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, hyperglycemia, metabolic syndrome, obesity and atherosclerosis, the compounds defined according to one of the claims 1) to 5).
  • 14) As novel medicines of use in dermatology in pathologies with an inflammatory component or resulting from abnormal cell differentiation, the compounds defined according to one of the claims 1) to 5).
  • 15) As novel medicines of use in the treatment of diseases such as psoriasis, acne, atopic dermatitis, cutaneous aging and photoaging, the compounds defined according to one of the claims 1) to 5).
  • 16) Pharmaceutical compound wherein it contains as an active ingredient a compound defined according to one of the claims 1) to 5) in association with a suitable excipient.
Priority Claims (1)
Number Date Country Kind
0502152 Mar 2005 FR national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/FR2006/000469 3/2/2006 WO 00 11/19/2007